High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition.
Cai J, Jacob S, Kurupi R, Dalton KM, Coon C, Greninger P, Egan RK, Stein GT, Murchie E, McClanaghan J, Adachi Y, Hirade K, Dozmorov M, Glod J, Boikos SA, Ebi H, Hao H, Caponigro G, Benes CH, Faber AC.
Cai J, et al. Among authors: ebi h.
Cell Rep. 2022 Jul 26;40(4):111095. doi: 10.1016/j.celrep.2022.111095.
Cell Rep. 2022.
PMID: 35905710
Free PMC article.